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Supplementary Fig. 1 Nucleotide-loading states of MFN2IM after purification 
a, HPLC chromatograph shows that freshly purified MFN2IM is loaded with GTP. 





Supplementary Fig. 2 Biochemical and structural features of MFN2IM 
a, The structure and topology diagram of the G domains of MFN2IM, MFN1IM (Protein Data Bank code 
5GOM), and dynamin-1 (2X2E). Secondary structural elements are not drawn to scale. The 
MFN2-specific 310 helices (η1
G
 and η2G) and β2’G are colored cyan. Note that because of extra 
secondary elements, element labeling of MFN2IM is slightly different from that of MFN1IM 
1
. 
b, Hydrophobic network within HD1. Side chains of the residues involved in the network are shown in 
the same color as the helices they belong to. 
c, The conventional HR2 is part of the HD1. ɑ4H comprising a large portion of HR2 is colored blue. 
and the rest part of MFN2IM is shown as hydrophobic surface representation. Note the extensive green 
patch underneath ɑ4H, which entails a tight hydrophobic association. 
d, Extended ɑ3H and ɑ4H of MFN2IM as compared to MFN1IM. MFN1IM is colored grey. ɑ3
H
 and ɑ4H of 
MFN2IM are colored green and blue, respectively. 
e, Distribution of residues in HD1. No intramolecular interaction exists between Met376 and Leu727, 
or between His380 and Asp725. 




Supplementary Fig. 3 Structure of truncated MFN2IM(T111D) 
a, Structural comparison between MFN2IM(T111D) (violet) and GDP-bound MFN2IM (pink). 
b, Details of the T111D mutation. The GDP molecule is shown as ball-and-stick model. Note that the 
side chain of negatively-charged Asp111 causes a space- and charge-hindrance to the accommodation 
of the phosphate groups of GDP. 
c, Binding of GTPγS and GDP with MFN2IM(T111D) measured by ITC. N/D, not determined. 
d, The coordination of Ca
2+
 of apo MFN2IM (upper-left) and MFN2IM(T111D) (right). Involved 
residues and acetate ion and are shown as ball-and-stick models. Electron density map is shown as blue 
mesh at a contour level of 1.0σ. 
e, GTP turnover rates of wild-type MFN2IM in the absence and presence of 10 mM CaCl2. Error bars 
indicate s.d. (n = 3). Source data are provided as a Source Data file. 
f, Dimerization property of nucleotide-free wild-type MFN2IM (left) and MFN2IM(T111D) (right) after 






Supplementary Fig. 4 The difference in the switch I of human mitofusins 
a, GTP turnover rates of wild-type MFN1IM/MFN2IM and corresponding mutants. Error bars indicate 
s.d. (n = 3). Source data are provided as a Source Data file. 
b, Sequence alignment of primate and non-primate mitofusins in switch I. The equivalent positions for 
Thr129 of human MFN2 are highlighted by red frames. Primates: hs, Homo sapiens; cs, Chlorocebus 
sabaeus; an, Aotus nancymaae; sb, Saimiri boliviensis; rb, Rhinopithecus bieti; po, Pongo abelii; nl, 
Nomascus leucogenys; pa, Papio anubis; pt, Piliocolobus tephrosceles; tg, Theropithecus gelada; ma, 
Macaca mulatta. Non-primates: ss, Sus scrofa; bt, Bos taurus; oa, Ovis aries; ec, Equus caballus; cl, 
Canis lupus familiaris; fc, Felis catus; oc, Oryctolagus cuniculus; gg, Gallus gallus; xt, Xenopus 
tropicalis; dr, Danio rerio; dm, Drosophila melanogaster. 
c, Comparison of the configuration of switch I between MFN2IM and MFN1IM (PDB code 5GO4) in the 
nucleotide-free state. Switch I regions are highlighted in yellow. Thr129 of MFN2IM, Ile108 and other 
residues involved in the hydrophobic network of MFN1IM are shown as stick-and-ball models. 





Supplementary Fig. 5 Dimerization test of MFN2IM 
a, Dimerization property of MFN2IM in different nucleotide-loading states. 
b, GTP-induced MFN2IM dimers slowly hydrolyze GTP while keeping associated. Left: RALS analysis 
of MFN2IM-GTP mixture after incubation for 2 h. Right: HPLC analysis of the nucleotides in different 
fractions of the dimer peak in gel-filtration. 
c, Dimerization property of freshly purified GTP-loaded MFN2IM. 
d, Location of the citrate ions (shown as spheres) at the G interface. 
e, Interactions of citrate with MFN2IM. The citrate ion and corresponding residues are shown as 
ball-and-stick models. Electron density map for citrate is shown as blue mesh at a contour level of 1.2σ. 
f, GTP turnover rates of MFN2IM in the absence and presence of 10 mM sodium citrate. Error bars 
indicate s.d. (n = 3). Source data are provided as a Source Data file. 
g, Dimerization property of MFN2IM in the presence of GDP after incubated with 10 mM sodium 




Supplementary Fig. 6 The differences of the MFN2IM and MFN1IM dimers 
a, Structural superposition of the G domains of the MFN1IM in the post-transition state, PDB code 
5GOM), MFN1IM in the transition state (PDB code 5YEW) and MFN2IM in the GDP-bound state. Note 
that the relative position of HD1 of MFN2IM is in between those of the two MFN1IM. 
b, Different residue contacts of the MFN2IM-GDP dimer, MFN1IM-GDP•BeF3  ¯ dimer (PDB code 
5YEW) and MFN1IM-GDP dimer (PDB code 5GOM). Corresponding residues are shown as 
ball-and-stick models. 
c, Dimerization property of MFN2IM G interface mutants in the presence of GDP•BeF3 .¯ 
d, Experimental process of spectroscopic liposome tethering assay. 
e, Purified and reconstituted TM-containing MFN1IM and MFN2IM were floated in a sucrose gradient. 
Top (T) and bottom (B) fractions were analyzed by SDS/PAGE and Coomassie blue staining. “A” 
denotes total proliposomes. Source data are provided as a Source Data file. 
f, GTP turnover rates of wild-type MFN2IM and the G interface mutants. Error bars indicate s.d. (n = 3). 




Supplementary Fig. 7 The design and quality control of the FRET assay 
a, The selected MFN1IM/MFN2IM sites of fluorescent labeling for the FRET assay, as indicated by red 
(Cy3) or green (Cy5) spheres. The distances between the fluorescence labels were estimated based on 
the crystal structures of MFN2IM-GDP and MFN1IM-GDP•BeF3  ¯ (PDB code 5YEW). The FRET 
signals can be detected only when associated MFN2IM and MFN1IM both change to the closed 
conformation. 
b, Site-specific dye-labeling of engineered MFN1IM and MFN2IM. The SDS-PAGE results show that 
altering exposed cysteines to serines (C156S for MFN1IM and C390S for MFN2IM) has successfully 
prevented non-specific fluorescent labeling. The introduction of designated mutations, namely A696C 
for MFN1IM(C156S) and A706C for MFN2IM(C390S), allows efficient labeling by fluorescent dyes. 
Source data are provided as a Source Data file. 
c, GTP turnover rates of MFN2IM and MFN1IM constructs used for FRET assays. Error bars indicate s.d. 
(n = 3). GTPase activity is not affected by introduced mutations. Source data are provided as a Source 
Data file. 
d, Dimerization property of MFN2IM and MFN1IM constructs used for FRET assays in the absence and 




Supplementary Fig. 8 Structural features of CMT2A-related mutants 
a-d, CMT2A-related mutation sites on the surface of MFN2. 
e, CD spectra of wild-type MFN2IM and CMT2A-related mutants. M.R.E. denotes mean residue 
epllipticity. 




Supplementary Table 1 Summary of CMT2A-related mutations 
Mutations Zone* Con.** E/B*** G/A**** 
Interaction 
MFN1/2***** 
 Mutations Zone* Con.** E/B*** G/A**** 
Interaction 
MFN1/2***** 
             
V69F2 V S B — —  R259L3 I/II I E — — 
L76P2 V S E H —  S263P4, 5 II I E — — 
L92R6 IV I B — —  V273G7 II I E C +++/++ 
L92P5, 8, 9 IV I B — —  Q276R10 II I E — — 
R94G11 III I E — —  Q276H
12, 13, 
14 
II I E C +++/+ 
R94Q2, 11, 13, 
14, 15, 16, 17, 18 
III I E H +++/+++  H277R9 II I E — — 
R94W4, 8, 10, 
11, 13, 17, 19 
III I E H +++/+++  H277Y20 II I E — — 
R104W21, 22, 
23, 24, 25 
I/II I E L -/+  R280H2, 8, 26 II I E H +++/++ 
T105M7, 11 I/II I E H -/-  F284Y18 V I E — — 
P123L9 I I E — —  E288D27 V I E — — 
G127V28 II I E L -/++  G298R13 V U E — — 
G127D5 II I E — —  E347V28 V I E — — 
H128R20 I I E — —  S350P4, 8 V I E — — 
N131S29 I I E H +++/+++  T356A30 IV I E — — 
C132T15 V I E L +++/+++  K357N18 III I E — — 
L146F31 V I B — —  H361Y10, 11 IV I E — — 
S156I20 V I E — —  T362M
5, 32, 
33 
IV I E — — 
A164V33 V I E — —  R364W
8, 10, 
11, 19, 34 
IV I E H +++/+ 
H165L35 II I E — —  R364Q
13, 14, 
20 
IV I E — — 
H165R4, 5, 8, 9 II I E H +++/++  R364P
11, 20, 
36 
IV I E H +++/+ 
H165Y9 II I E — —  M376L6 V I B C +++/+++ 
I203M13 V N B — —  M376I9, 28 V I B — — 
T206I10 V I E — —  M376V13 V I B — — 
D210V37 V I E — —  M376T5 V I B — — 
I213T7 V I B — —  S378P25 V I E — — 
D214N33 V I E — —  Q386P9 V U E — — 
F216S32 V I E — —  C390F11 V U E — — 
L218P38 V I E H +++/++  C390R33 V U E — — 
F223Y39 V I B — —  R400P23 V I E — — 
F223L18 V I B — —  R707W17, 33 V U E — — 
L233V34 V I E — —  L710P9 V I E — — 
T236M18 II I E — —  A716T11, 17 V U E — — 
V244M18 V I B — —  L724P40 V I B — — 
L248V11 IV I E H +++/+++  A738V40 V I E — — 
S249F24 IV I E ― —  W740S2, 11 V U E C +++/+++ 
R250W9 IV S E — —  W740R19 V U E — — 
R250Q6, 9 IV S E — —  W740C20 V U E — — 
P251A2 IV I E — —  E744M34 V I E — — 
P251R6, 11 IV I E L ++/++  L745P20 V I B — — 
P251L41 IV I E H +++/++  M747T20 V U E — — 
N252K13 IV I E — —  H750P11 V U E — — 
*Zone: I, nucleotide-binding site; II, G interface; III, hinge 2; IV, G domain-HD1 interface; V, other area. 
**Conservation between human MFN1 and MFN2: I, identical; S, similar; U, unconserved. 
***Exposed (E) or buried (B). 
****GTPase activity (G/A) compared to wild-type: H, (statistically) higher; C, comparable; L, lower. 
Significance was calculated with Student’s t-test (n = 3). Cut-off value: p < 0.05. 




Supplementary Table 2 List of primers 
 Primers Sequence 5’-3’ 
1 pET-28_MFN2IM-FW GGCGGATCCGCTGAGGTGAATGCATCCCCAC 
2 pET-28_MFN2IM-RE GGCCTCGAGCTATCTGCTGGGCTGCAGGTAC 
3 MFN2IM-overlap-FW GAGCGGCAAGACCGAACCCGGGAGAACCTGGAGCAGG 
4 MFN2IM-overlap-RE CAGGTTCTCCCGGGTTCGGTCTTGCCGCTCTTCACGC 
5 MBP-tagged MFN1IM-FW ATTTGCGGCCGCAGCTGAGGTGAATGCATCCCC 
6 MBP-tagged MFN1IM-RE CCGCTCGAGCTATCTGCTGGGCTGCAGGTAC 
7 MBP-tagged MFN2IM-FW GGTTCTGTCGACTCTGCGGCCGCAGCTGAGGTGAATGCATCCCCAC 
8 MBP-tagged MFN2IM-RE GTGGTGGTGGTGGTGCTCGAGCTATCTGCTGGGCTGCAGGTAC 
9 PGEX-6P-3_MFN2IM-FW CGCGGATCCATGGCTGAGGTGAATGCATCCCCACTTAA 
10 MFN2IM-TM-RE1 ACCAGAATACCCATGCTAGCGCTCGCAGCCGATCGGTCTTGCCG 
11 MFN2IM-TM-FW1 CGGCAAGACCGATCGGCTGCGAGCGCTAGCATGGGTATTCTGGT 
12 MFN2IM-TM-RE2 GGTTCTCCCGGGTGGCTGCGGATGCGTAAACATACAGCAGG 
13 MFN2IM-TM-FW2 CCTGCTGTATGTTTACGCATCCGCAGCCACCCGGGAGAACC 
14 PGEX-6P-3_MFN2IM-RE CCGCTCGAGTTATCTGCTGGGCTGCAG 
15 PGEX-6P-3_MFN1IM-FW CGCGGATCCATGGATTACAAGGATGACGACGATAAGGCCGAA 
16 MFN1IM-TM-RE1 ACGATGATGATGCCCATGCTACTGCCGCCACTGCCACTGCCACTGCC 
17 MFN1IM-TM-FW1 GGCAGTGGCAGTGGCAGTGGCGGCAGTAGCATGGGCATCATCATCGT 
18 MFN1IM-TM-RE2 TGCGATACTTCCGGAACCGTACAGGTACAGTGCACCAT 
19 MFN1IM-TM-FW2 GGTGCACTGTACCTGTACGGTTCCGGAAGTATCGCA 
20 PGEX-6P-3_MFN1IM-RE CCGCTCGAGTTAAGCGTAATCTGGAACATCGTATGGGTAGCTTTCTTCGTT 
21 PGEX-6P-1_MFN2IM-FW GGCGGATCCGCTGAGGTGAATGCATCCCCAC 
22 MFN2IM-TMSac1-FW1 GCCTTGACCGTTTTAGGTGCTACGATATTTTTTCCTAAAGATAGATTTACCAGCAGTAAGACCCGGGAGAACCTGGAGCAG 
23 MFN2IM-TMSac1-RE1 CGTAGCACCTAAAACGGTCAAGGCTGCGCAAATGATCATTGGGATCAGCTGAATATATCGGTCTTGCCGCTCTTCACGC 
24 MFN2IM-TMSac1-FW2 CGATTGTCTTGGCGCTTTCAACCAAATTCATGTTTAAGAACGGTATTCAGTTTGTCACCCGGGAGAACCTGGAGCAG 
25 MFN2IM-TMSac1-RE2 GGTTGAAAGCGCCAAGACAATCGACGCACCTGCAAAATACAGCAAATTCTTACTGCTGGTAAATCTATCTTTAGG 
26 PGEX-6P-1_MFN2IM-RE GGCCTCGAGCTATCTGCTGGGCTGCAGGTAC 
27 PGEX-6P-1_MFN1IM-FW GGCGGATCCATGGCAGAACCTGTTTCTCCACTG 
28 MFN1IM-TMSac1-FW1 GCCTTGACCGTTTTAGGTGCTACGATATTTTTTCCTAAAGATAGATTTACCAGCAGTAAGGCTAGATTACCCAAAGAAATAGATCAG 
29 MFN1IM-TMSac1-RE1 CGTAGCACCTAAAACGGTCAAGGCTGCGCAAATGATCATTGGGATCAGCTGAATATATGAATAATGCCTTTTATCTTCAGCTG 
30 MFN1IM-TMSac1-FW2 CGATTGTCTTGGCGCTTTCAACCAAATTCATGTTTAAGAACGGTATTCAGTTTGTCGCTAGATTACCCAAAGAAATAGATCAG 
31 MFN1IM-TMSac1-RE2 GGTTGAAAGCGCCAAGACAATCGACGCACCTGCAAAATACAGCAAATTCTTACTGCTGGTAAATCTATCTTTAGG 




34 pQCXIP_MFN2(I126D)-RE CTGTGCCCCCAACCCGCAGGAAGCAATTGGTGGTATGACCATCC CCAGATGGCAG 
35 pQCXIP_MFN2-FW GGGAAGAGCACCGTGATCAA 
36 MFN2(N161A)-FW TGGGCCAGTTGGGCCACAGTCTTGAC 
37 MFN2(N161A)-RE GTCAAGACTGTGGCCCAACTGGCCCA 
38 pQCXIP_MFN2-RE AGCAGCGGTCAGACAGGTT 
39 MFN2(K307A)-FW CTGAGAACCTCCGCGGCAGACACGAA 
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